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Background: Pain conditions of the musculoskeletal system are very common and have tremendous
socioeconomic impact. Despite its high prevalence, musculoskeletal pain remains poorly understood and
predominantly non-specifically and insufficiently treated.
The group of chronic musculoskeletal pain patients is supposed to be heterogeneous, due to a multitude of
mechanisms involved in chronic pain. Psychological variables, psychophysiological processes, and neuroendocrine
alterations are expected to be involved. Thus far, studies on musculoskeletal pain have predominantly focused on
the general aspects of pain processing, thus neglecting the heterogeneity of patients with musculoskeletal pain.
Consequently, there is a need for studies that comprise a multitude of mechanisms that are potentially involved in
the chronicity and spread of pain. This need might foster research and facilitate a better pathophysiological
understanding of the condition, thereby promoting the development of specific mechanism-based treatments for
chronic pain. Therefore, the objectives of this study are as follows: 1) identify and describe subgroups of patients
with musculoskeletal pain with regard to clinical manifestations (including mental co-morbidity) and 2) investigate
whether distinct sensory profiles or 3) distinct plasma levels of pain-related parameters due to different underlying
mechanisms can be distinguished in various subgroups of pain patients.
Methods/Design: We will examine a population-based chronic pain sample (n = 100), a clinical tertiary care sample
(n = 100) and pain-free patients with depression or post-traumatic stress disorder and pain-free healthy controls
(each n = 30, respectively). The samples will be pain localisation matched by sex and age to the population-based
sample. Patients will undergo physical examination and thorough assessments of mental co-morbidity (including
psychological trauma), perceptual and central sensitisation (quantitative sensory testing), descending inhibition
(conditioned pain modulation, the diffuse noxious inhibitory control-like effect), as well as measurement of the
plasma levels of nerve growth factor and endocannabinoids.
Discussion: The identification of the underlying pathophysiologic mechanisms in different subgroups of chronic
musculoskeletal pain patients will contribute to a mechanism-based subgroup classification. This will foster the
development of mechanism-based treatments and holds promise to treat patients more sufficient.
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Chronic pain conditions of the musculoskeletal system
are common and of high socioeconomic relevance [1-4].
This is especially true for pain conditions with widely
unknown pathogeneses, such as non-specific chronic
back pain (CBP), chronic widespread pain (CWP), and
fibromyalgia syndrome (FMS). In addition, the preva-
lence of these conditions and the demand for consult-
ation and treatment have increased over recent years
[5,6], which results in high direct and indirect costs
[1,3,7,8].
However, therapeutic approaches in chronic musculo-
skeletal pain patients are often of minor success [9-16].
This is likely because the aetiology and pathogenesis of
chronic musculoskeletal pain are still widely unknown. As
a result, treatment for this condition involves predomin-
antly unspecific interventions, although the group of
chronic musculoskeletal pain patients is believed to be
heterogeneous [17,18]. Differences in response to the
same treatment in patients with the same disease could
be explained by different underlying mechanisms con-
tributing to the generation and maintenance of pain
[19,20]. The situation is complicated by the finding that
the same disease can derive from various pathophysio-
logical mechanisms. Conversely, the same pathophysio-
logical mechanism may be of interest in distinct diseases
[20].
The heterogeneity is supported by strong hints that
subgroups exist that differ in terms of aetiopathology,
clinical symptomatology, and psychophysiological pat-
terns. A recent study revealed distinct somatosensory
profiles in CBP and FMS: FMS patients showed
increased sensitivity for different pain modalities in all
measured body areas, which suggests central disinhib-
ition (or a deficient pain inhibitory system) as a potential
mechanism. CBP subjects, in contrast, exhibited loca-
lised alterations within the affected segment. Such
alterations may be due to peripheral sensitisation [21].
This finding is in accordance with the main hypothesis
of a mechanism-based diagnosis in chronic pain syn-
dromes, which proposes that defined symptoms and
signs reflect possible underlying neurobiological pain
mechanisms [19,22]. Consequently, these subgroups
should be treated with specific mechanism-based
approaches, but to date, they have been treated with the
same non-specific multimodal treatment programs.
Therefore, the assessment of chronic pain and research
identifying various factors associated with the develop-
ment, maintenance, and spread of chronic pain, includ-
ing their neurobiological correlates, is highly relevant.
Chronic pain has been found to be associated with a
higher prevalence of mental co-morbidity. Patients with
CBP [23,24], CWP [25], and FMS [26] suffer from men-
tal disorders significantly more often than pain-freecontrols. This finding is especially true for anxiety disor-
ders and mood disorders, which were found to have
prevalence rates of 20.9% and 12.7%, respectively, in a
population-based sample of patients with chronic back
pain [23]. Of further interest is the role of psychological
trauma, which has been neglected in previous research.
Traumatic events have higher prevalence rates in patients
with pain compared to pain-free controls or patients with
other diseases [27-29]. Concerning traumatic experiences,
it was suggested that multiple traumas have a cumulative
effect on physical health, including back pain and that
the impact of the trauma on health may be independent
of post-traumatic stress disorder (PTSD) symptomatol-
ogy [30,31].
The assessment of chronic pain and mental comorbid-
ity on a psychobiological basis may detect common
underlying pathophysiological changes. With regard to
pain processing there are studies that suggest a role for
central disinhibition mechanisms in depression and, to a
lower extent, in patients with FMS compared to healthy
controls [32]. Alterations in pain processing among
patients with depression or FMS were reported previ-
ously, but this study found that hyperalgesia was more
pronounced in patients with FMS than in those with de-
pression [33]. In patients with FMS with comorbid de-
pression or anxiety, pain processing was not altered in
comparison to patients with FMS alone [34]. Thus there
seems to be an association of chronic pain or depression
with altered pain processing, although chronic pain and
comorbid depression did not interact with pain
processing.
In regard to anxiety disorders and the neglected role
of trauma, a study by Defrin et al. described a unique
sensory profile of hyposensitivity to non-noxious stimuli,
accompanied by hypoalgesia to at-pain-threshold nox-
ious stimuli and hyper-reactivity to suprathreshold nox-
ious stimuli in patients with PTSD and chronic pain
compared with healthy controls [35].
This pattern clearly differs from other patient groups
with chronic pain, such as those with fibromyalgia, who
tend to exhibit pain hypersensitivity [21,36], and from
alterations in PTSD, in which context a decreased sensi-
tivity to painful stimuli has been reported [37,38]. The
results reported by Defrin et al. appear to be a hybrid of
what has been found in pain-free PTSD patients and
PTSD-free pain patients: decreased sensitivity to non-
painful stimuli and increased hyperreactivity to painful
stimuli. Sensory processing in anxiety disorders other
than PTSD is believed not to differ from processing in
healthy controls [35]. Another aspect of the psychobiol-
ogy of pain is pain inhibition. It was found that pain in-
hibition is deficient in FMS patients but normal in those
with depressive disorder [33]. Another study reports evi-
dence that pain inhibition in FMS is more pronounced in
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to those with FMS alone [39]. However, due to hetero-
genic sample selection and different testing methods, the
results in regard to pain processing and pain inhibition
in chronic pain and mental disorders are inconsistent
and partially contradictory [40]. Therefore, a compre-
hensive measurement of the clinical manifestation and
psychobiological aspects of chronic pain is necessary.
To challenge the topic of a mechanism-based sub-
group classification of chronic pain patients and to es-
tablish specific mechanism-based treatments [41],
further variables of interest must be considered to guar-
antee a more holistic approach, compared to that pur-
sued in prior research. Therefore, we developed a
theoretical framework (Figure 1), which investigates the
role of chemical sensitisation (nerve growth factor;
NGF) [42-46], the endocannabinoid system [47,48], and
other psychological variables (e.g. early stress exposure,
stress and pain coping, resilience) [49-51] as well as gen-
etic variables [52-54] in addition to mental comorbidity
and psychophysiological patterns. NGF is an important
key mediator of some forms of persistent pain and plays
an important role in the switch from acute to chronic pain
as well as the spatial spread of pain [42-46]. The endocan-
nabinoid system refers to a group of neuromodulatory
lipids that is relevant for pain memory and pain extinc-
tion [47,48]. Accordingly, these variables have proven to
be of interest in chronic pain and to be promising in
its treatment. In line with that, the current study
addresses the association between the clinical manifest-
ation of chronic musculoskeletal pain (including mental
comorbidity) and neurobiological changes.
Therefore, the purpose of the present study is to 1)
identify and describe subgroups of patients with muscu-
loskeletal pain with regard to clinical manifestation (in-
cluding mental comorbidity), 2) investigate whether
distinct sensory profiles due to different underlying
mechanisms can be distinguished in different subgroupsFigure 1 Theoretical framework of our project.of pain patients 3) and to measure plasma nerve growth
factor levels and to analyse distinct endocannabinoid
profiles in different subgroups of pain patients.
Methods
This study is part of the consortium ‘Localized and Gen-
eralized Musculoskeletal Pain: Psychobiological Mechan-
isms and Implications for Treatment (LOGIN)’ funded
by the German Federal Ministry of Research and Educa-
tion (01EC1010A-F). More details concerning LOGIN
can be found elsewhere [55,56]. This report focuses on
subproject number six (SP6) ‘Subgroups Characterised
by Psychological Trauma, Mental Co-morbidity, and
Psychobiological Patterns and Their Specialised Treat-
ment’. All participants must provide written informed
consent before inclusion in the study. The study has
been approved by the Ethics Research Committee of the
Faculty of Medicine, University of Heidelberg (S-261/
2010) and will be carried out in compliance with the
Helsinki Declaration.
Design
The study uses a descriptive and exploratory design. We
will include 200 patients with chronic musculoskeletal
pain from different settings (a population-based setting
and a tertiary care setting) and 90 controls (pain-free
patients with PTSD, depression, and healthy controls
without mental disorders). All participants will undergo
a physical examination. The relevant sociodemographics
and measures of clinical manifestations of chronic pain
are reported in Table 1: measurements of potential
pathophysiological mechanisms are reported in Table 2.
Samples and patient recruitment
We will recruit patients with non-specific chronic mus-
culoskeletal pain as well as control subjects that are
not in pain: 1) Population-based sample: In a previous
population-based study (“Generalization of Pain: A
prospective population-based survey with clinical
examination” as part of the German Back Pain Re-
search Network, supported by the Federal Ministry of
Education and Research; [21,23,57,58]), we established
a representative sample of patients with chronic local
and chronic widespread back-pain. For the present
study, 100 patients from this representative study sam-
ple will be randomly recruited. 2) Tertiary care setting:
We will recruit 100 consecutive musculoskeletal pain
patients from the tertiary care Musculoskeletal Pain
Centre at the University Hospital Heidelberg. 3) Con-
trol subjects: To determine whether the results are
specific for pain, we will further investigate three
groups of pain-free patients: a) PTSD patients (n = 30),
b) patients with depression (n = 30), and c) healthy con-
trols (n = 30). Patients with PTSD and depression will
Table 1 Variables and methods used to assess clinical manifestations of chronic non-specific musculoskeletal pain
Questionnaires Variables
Chronic Pain Grade Questionnaire (CPG)* [65,66] Severity of chronic pain problems (disability, pain intensity)
Pain Experience Scale (SES) [64] Sensory and affective descriptors of pain
12-Item Short-Form Health Survey (SF-12)* [74,75] Health-related quality of life
Resilience Scale (RS11)* [97,98] Resilience (personal competence, acceptance of self and life)
Hospital Anxiety and Depression Scale (HADS-D)* [99,100] Anxiety and depression
Childhood Trauma Questionnaire (CTQ)* [72,73,101] Childhood and adolescence maltreatment (physical and emotional abuse,
sexual abuse, physical and emotional neglect)
Pain drawing (pain location) [62] [63] [6] Perceived location(s) of pain will be assessed using digitised pain drawings.
Classification into categories of chronic local and chronic widespread pain.
Sociodemographics (self-report questions) Age, sex, marital status, education, employment status
Interviews
Structured Clinical Interview for DSM-IV Axis I
Disorders + Axis II (SCID I + II)* [69]
DSM-IV Axis-I and Axis-II mental disorders
Physical examination
ACR Criteria for Fibromyalgia (ACR Classification)
[62] [102]
Tenderpoint count and documentation of specific symptoms
Physical Impairment Scale (PIS) [67] Physical impairment (total flexion, total extension, average lateral flexion,
straight leg raising, spinal tenderness, bilateral active straight leg raising, and sit-up)
Back Performance Scale (BPS) [68] Disability. Tests of daily activities (Sock Test, Pick-up Test, Roll-up Test,
Fingertip-to-Floor Test, and Lift Test)
* German Version.
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at the University Hospital of Heidelberg. Healthy con-
trols will be recruited by flyers posted around the local
community. All groups will be matched with respect
to age, sex, and (if appropriate) pain location to our
population-based sample. Thus, we will include at least
200 patients with non-specific chronic pain and 90
pain-free subjects.
Inclusion and exclusion criteria
The inclusion criteria for pain samples are non-specific
chronic musculoskeletal pain lasting for ≥ 45 days during
the past three months, at least 18 years of age, and flu-
ent German language skills. All control participantsTable 2 Methods used to assess the potential mechanisms in
Measures Variables




Conditioned Pain Modulation (CPM, the diffuse






Nerve Growth Factor (NGF) Plasma NGF le
Endocannabinoids + related lipids (ECs) EC (anandamid
palmitoyl etha
plasma (large-
Genetics 2* 9 ml EDTA(participants with PTSD, depression, and healthy con-
trols) should be pain-free. Because the point prevalence
of back pain in the German population was more than
one third and the 1-year prevalence was higher than 75%
[57], the recruitment of patients that were absolutely
pain free within the last three months, will not be feasible
and will not reflect reality. Therefore, we aim to recruit
only absolutely pain-free participants. If this is not pos-
sible, we will define pain-free as follows: 1) less than one
day (< 24 hours) spent in pain per week within the last
three months. 2) Pain intensity < 3 on an 11-point nu-
meric rating scale on the days when the patient is in pain.
3) Pain does not interfere with normal activities or work.
These criteria are adapted from standardised definitionsvolved in chronic non-specific musculoskeletal pain
e profiles of somatosensory functions (thermal and mechanical detection
holds, vibration thresholds, and pain sensitivity to sharp and blunt
muli). Discrimination between local vs. generalised and peripheral
vous mechanisms.
pain inhibitory mechanism that inhibits nociceptive activity arising from
imary fibres at multiple levels of the dorsal horn, resulting in diffuse pain
se descending pain pathways originate from the brainstem and have
ibitory actions on nociceptive activity, thereby affecting pain perception.
vels (proximity ligand ELISA techniques)
e (AEA), 2-arachidonoyl glycerol (2-AG), 1-arachidonoly glycerol (1-AG),
nol amine (PEA), oleoyl ethanol amine (OEA), arachidonic acid) in human
scale lipidomic profiling using the LC-MS/MS QTrap ABI5500)
tubes, stored for the second funding period
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must also be pain free on the day of participation in the
study. Patients who have a previous history of chronic
pain will be excluded. Participants with PTSD and de-
pression must fulfill DSM-IV diagnoses of the respective
mental disorder. Patients with PTSD must be free of
affective disorders, and patients with depression must be
free of anxiety disorders. Healthy controls are not
allowed to meet any DSM-IV diagnosis. The exclusion
criteria are specific pathologies of CBP (e.g., spinal canal
stenosis, disc hernia, spondylolisthesis, infection, malig-
nancy, rheumatic and systematic inflammatory disorders,
and fracture), sciatica pain ≥ than back pain, diseases
affecting sensory processing (diabetes, alcohol or sub-
stance abuse, neuropathy, inflammatory diseases), pain
or surgery at the dorsum of the hand or back surgery in
the past three years (because the hand und back are to be
subjected to investigation), and cognitive impairment.
Procedure
Chronicity of pain
The number of painful days in the last three months
will be determined by a questionnaire and discussed
with a physician to rule out misunderstandings. To be
classified as suffering from chronic pain, the subject
must report experiencing back pain on ≥ 45 days in the
last three months.
Clinical examination
To verify the inclusion and exclusion criteria, all partici-
pants will be questioned about their past medical history
and about co-morbidities (neuropathy, diabetes, relevant
alcohol consumption, infections, inflammatory diseases,
disc hernia, previous severe injuries). Patients will also
receive a physical examination (general, rheumatological,
orthopaedic, and neurological), including blood tests
(and if indicated further technical investigations such as
x-ray or MRI) with special attention paid to findings that
indicate a specific origin of back pain. Therefore, the
“red flags” (hints of the presence of serious pathology
according to the Agency for Health Care Policy and Re-
search Low Back Guidelines) and yellow flags will be
considered [61], and former medical reports and dis-
charge letters will be taken into account whenever avail-
able. In the case of signs of serious pathological findings,
participants will be excluded, and a further investigation
will be advised. Painful tender points will be identified
by tenderness examination using ACR criteria [62].
Measures of clinical manifestation
The clinical manifestations of pain will be considered
using the pain dimensions (pain intensity, pain location/
extent, pain quality, and pain affect), disability/ impair-
ment (subjective as well as objective measures), andpsychological measures (mental comorbidity, early life
stress, health-related quality of life, and resilience).
Patients will be clustered in homogeneous groups
according to their clinical manifestation. In subsequent
analyses, we will test whether the clinical manifestation
corresponds with specific mechanisms (see below).
Pain dimensions
There are at least four dimensions of pain experience
that can be distinguished. These are intensity, location,
quality, and affect. Pain intensity: Pain intensity is
defined as how much a person hurts. It will be mea-
sured using a numerical rating scale, ranging from 0
‘no pain’ to 10 ‘worst pain imaginable’. Pain location:
Pain location can be defined as the perceived location
(s) of pain sensations that patients have on or in their
body. Spatial distribution patterns (local vs. referred
pain) will be assessed using a digitised pain drawings
[63]. Moreover, categorisation as CLP, CWP, and FMS
will be based on the ACR criteria [62] and a more
precise definition elaborated by Harkness et al. [6].
Therefore, each participant will be asked to complete a
body pain diagram, marking all areas where pain is
experienced. Afterwards, the pain diagram will be dis-
cussed jointly by the participant and the physician to
rule out any misunderstandings. Pain quality and pain
affect: Pain quality refers to the specific physical sensa-
tions associated with pain. Pain affect is the degree of
emotional arousal caused by the sensory experience of
pain. The affective and sensory dimensions of pain will
be measured using the Pain Experience Scale (SES).
The SES is the standard instrument of the German
chapter of the International Association for the Study
of Pain. The SES consists of 10 items on a sensory
subscale (e.g., ‘throbbing’, ‘wrenching’ or ‘stinging’) and
14 items on an affective subscale (e.g., ‘exhausting’,
‘fearful’, or ‘unbearable’). The response format is a
four-stage format (0 ‘not appropriate’; 1 ‘somewhat ap-
propriate’; 2 ‘generally appropriate’; 3 ‘fully appropri-
ate’). The sensory score of the SES is the mean of all
sensory items; the affective score of the SES is the
mean of all affective items. The retest-reliability of the
SES lies between .89 and .96, and Cronbach’s Alpha
lies between .72 and .92 [64].
Disability/ impairment
Chronic pain grade (CPG) The CPG assesses the sever-
ity of chronic pain problems. It measures pain intensity
and disability in regard to work and daily activities via
patients’ self-reports. The CPG comprises 6 items that
can be answered on an 11-point numerical rating scale
ranging from ‘0’ to ‘10’. The number of days during
which the patient experienced a disability during the
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graded in four hierarchical classes (Grade I, low disabil-
ity – low intensity; Grade II, low disability – high inten-
sity; Grade III, high disability – moderately limiting;
Grade IV, high disability – severely limiting). The CPG
has proven reliability (α= .82) and validity [65,66]. To
objectify impairment and disability, we will use the Phys-
ical Impairment Scale and the Back Performance Scale.
Physical impairment scale (PIS) The PIS was devel-
oped as a simple and standardised clinical observation
to evaluate physical impairment in patients with chronic
low back pain. The test battery combines objective phys-
ical findings indicating current functional limitations
due to pain. It consists of seven tests measuring lower
back movement (total flexion, total extension and aver-
age lateral flexion as measured with the inclinometer),
straight leg raises, spinal tenderness and strength (bilat-
eral active straight leg raises, sit-ups). The measurements
are translated into values of 0 or 1 according to cut-off
values and summed. As subjective disability in non-
specific low back pain is not explained by anatomic or
structural impairment, the PIS measures functional limi-
tation as influenced by the patient’s pain behaviour. The
PIS is able to discriminate between pain patients and
healthy controls and is related to self-reported disability
in the activities of daily living [67].
Back performance scale (BPS) The BPS is an objective
clinical assessment tool that can be used to observe
self-reported activity limitations in daily functioning
caused by lower back pain. The BPS consists of five
tests of daily activities (Sock Test, Pick-up Test, Roll-up
Test, Fingertip-to-Floor Test, and Lift Test) frequently
reported to be limited in back pain patients. Each per-
formance is evaluated by the observer according to op-
erational score definitions and then summed. The five
tests are combined to obtain a performance measure of
mobility-related activities requiring sagittal-plane mobil-
ity. The BPS is able to discriminate between pain
patients with different return-to-work statuses and is
sensitive to change. Cronbach’s α was .73 [68].
Psychological measures
Structured clinical interview for DSM-IV (SCID) To
examine the prevalence and the type of mental co-mor-
bidity, the SCID interview, which consists of two parts,
will be applied [69]. The SCID is a comprehensive and
highly reliable and valid instrument [70]. The SCID-I is
a semi-structured interview for the evaluation of major
DSM-IV Axis-I diagnoses. With the SCID-I, it is pos-
sible to derive both a current and a previous history of
psychiatric illness. The SCID-II procedure for assessingpersonality disorders (PD) is a two-stage process. First,
subjects complete a 120-item questionnaire with ques-
tions based on the criteria from the DSM-IV. In the
second stage, a semi-structured interview is adminis-
tered. Positive answers must be re-evaluated by the
interviewer to diagnose Axis-II PD. According to the
SCID-II protocol, we will interview only those subjects
who achieve the cut-off (a specified number of positive
answers in a specific PD section) on the questionnaire
[69]. All SKID interviews will be conducted by two psy-
chologists with graduate training in clinical psychology.
To ensure diagnostic reliability, all interviews will be
audiotaped. One-fifth of the interviews will be randomly
selected and rated by both psychologists. A kappa coef-
ficient will be calculated to assess inter-rater reliability.
Both psychologists will conduct 10 SKID interviews in
a pilot phase. In cases of low inter-rater agreement fur-
ther, training will be conducted by an experienced
psychiatrist.
The Hospital Anxiety and Depression Scale (HADS-D)
will be used to determine the severity of anxiety and de-
pression. The HADS-D was especially developed for
patients with somatic diseases and thus excludes phys-
ical symptoms. Each scale consists of seven items that
measure anxiety and depression via the patient’s self-
report with a four-stage response format. The HADS-D
has good reliability (subscale depression: α= .81; subscale
anxiety: α= .80) and validity [71].
Childhood Trauma Questionnaire (CTQ The German
Version of the CTQ will be used to measure early stress
exposure. The CTQ measures maltreatment during
childhood and adolescence and will be applied because
it captures factors that are relevant to chronic pain [50]
that are neglected by the SKID. The CTQ consists of
five subscales (‘emotional abuse’, ‘physical abuse’, ‘sexual
abuse’, ‘emotional neglect’, and ‘physical neglect’). Cron-
bach’s α ranges from .89 to .96, except for the subscale
‘physical neglect’ which yields an α of .62 [72,73].
12-Item short form health survey (SF-12) The health-
related quality of life (HRQoL) will be measured with
the SF-12. The SF-12 consists of 12 items on eight scales
(‘physical functioning’, ‘role limitations due to physical
problems’, ‘bodily pain’, ‘general health’, ‘vitality’, ‘social
functioning’, ‘role limitations due to emotional problems’,
and ‘perceived mental health’). Response categories vary
from 2 to 6 and can be transformed to scale scores ran-
ging from 0 (‘the worst’) to 100 (‘the best’) [74,75].
Resilience scale (RS-11) Resilience is a personality
characteristic that moderates the negative effects of
stress and promotes adaption. Thus it avoids any poten-
tially negative effects of stress. Resilience will be
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tors – ‘acceptance of self and life’ and ‘personal compe-
tence’ – with a seven-point response format ranging
from 1 ‘disagree’ to 7 ‘agree’. Thus, scores can range
from seven to 77, with higher scores reflecting higher re-
silience. The RS-11 has very good reliability (α= .91).
Sociodemographic variables
Sex, age, education, employment status, marital status
and further sociodemographic variables will by captured
by a questionnaire.
Measures of chronic pain mechanisms
We will determine whether the patient’s clinical manifes-
tations of pain correspond with various specific potential
pain mechanisms. In our study, potential mechanisms are
captured through quantitative sensory testing (QST), the
evaluation of conditioned pain modulation (CPM, the dif-
fuse noxious inhibitory control-like effect), and analyses of
nerve growth factor (NGF) plasma levels and endocanna-
binoid (ECs) profiles. Such potential mechanisms include
peripheral sensitisation, central sensitisation, disinhibition,
allodynia, and endogenous descending pain modulation.
Psychophysiological mechanisms
Quantitative Sensory Testing (QST) Somatosensory
function will be assessed using the comprehensive QST
protocol developed as part of the German Research Net-
work on Neuropathic Pain (DFNS). Seven tests measuring
13 parameters (warm detection threshold, cold detection
threshold, thermal sensory limen, paradoxical heat sensa-
tion, cold pain threshold, heat pain threshold, mechanical
detection threshold, mechanical pain threshold, mechan-
ical pain sensitivity, dynamic mechanical allodynia, wind-
up ratio, vibration detection threshold, and pressure pain
threshold) [76] will be conducted. QST testing covers all
relevant aspects of the somatosensory system including
large and small fibre function as well as signs of central
sensitisation (dynamic tactile allodynia, punctate mechan-
ical hyperalgesia). This way, detailed profiles of somato-
sensory function will be obtained for the tested body
areas. The test sites will be distributed throughout the
paraspinal muscles (5 cm±0.5 cm next to the midline on
the autochthon back muscles [L1 to S1]) and on the
dorsum of the ipsilateral hand.
Conditioned pain modulation (CPM) Inhibitory pain-
modulating mechanisms will be assessed using the CPM,
a diffuse noxious inhibitory control-like effect [77-79].
The difference in pressure pain threshold (PPT) before
and after the induction of DNIC by phasic heat pain
(PHP) will be measured. The appropriate temperature
for PHP will be determined by measurement of the heatpain threshold (HPT). The PHP will oscillate ± 1°C
around the PHP-temperature. The ratings of PHP pain
intensity will be assessed using a computerised Visual
Analogue Scale (VAS). The HPT will be obtained using
ramped stimuli (1°C/s, 32°C baseline, 0°C and 50°C cut-
offs, 8 cm2 thermode), which will be terminated when
participants press a button. The mean of three consecu-
tive measurements will be calculated. The PPT will be
calculated as the mean of three consecutive measure-
ments over the paraspinal muscles (5 cm± 0.5 cm next
to the midline on the autochthon back muscles [L1 to
S1]; site contralateral to the QST).
Neurobiological measures
Nerve growth factor (NGF) NGF levels in human blood
samples will be determined using proximity ligand Elisa
techniques. Endocannabinoids (ECs): EC (anandamide
(AEA), 2-arachidonoyl glycerol (2-AG), 1-arachidonoly
glycerol (1-AG), palmitoyl ethanol amine (PEA), oleoyl
ethanol amine (OEA), arachidonic acid) analyses of human
blood samples will be performed by large-scale lipidomic
profiling using the LC-MS/MS QTrap ABI5500. All ana-
lyses of NGF and ECs will be performed in collaboration
with our consortium partners.
Sample size estimation
A sample of more than 200 musculoskeletal pain
patients (population-based sample and tertiary care
sample) will be acceptable in order to recruit a suffi-
cient number of “cases” with different clinical manifes-
tations (e.g., local vs. generalised pain, different levels
of pain affect, anxiety disorders, mood disorders, no
mental comorbidity). To estimate the number of
patients in different subgroups, we will refer to data
from our population-based study. Approximately 61.8%
of the patients in our population-based study had
chronic local pain (CLP), and 38.2% had chronic wide-
spread pain (CWP). We also found a prevalence of
12.7% for depression and 20.9% for anxiety disorders
(using the SCID-I). The prevalence of depression and
anxiety may be higher in a tertiary care pain setting,
as reported by others [80,81]. Therefore, we expect
group sizes that will be sufficient to gather abundant
information regarding clinical manifestations. We also
consulted recent QST studies and a review regarding
DNIC to estimate the required group sizes. For DNIC
testing, a systematic review [82] evaluated studies with
an average group size of 20. A group size of 20 to 30
is also commonly used in recent QST studies
[21,63,83]. We therefore expect our group sizes to be
appropriate for the investigation of distinct sensory
profiles. Studies investigating endocannabinoids used
sample sizes between n = 10 and n = 20 patients per
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.80 (e.g. [84,85]). Studies with NGF have reported ef-
fect sizes between 2.02 and 4.31 [44,86]. With regard
to pain mechanisms, small sample sizes are sufficient
to compare subgroups. This will also apply for the
groups of pain-free patients with PTSD, depression,
and healthy controls (each n= 30, respectively).
Quality assurance
To ensure that the measurements are reliable and high
in quality, the project will have a pilot phase. In this
pilot phase the study staff will be trained in the study
procedures (if necessary) and conduct paired measure-
ments to ensure reliability and validity. The pilot phase
will be finished when the reliability and validity of the
measurements has been verified. The study protocols
will be tested and adapted if necessary.
Statistical analyses
Descriptive statistics will be presented with means and
standard deviations for continuous variables and abso-
lute numbers and percentages for categorical variables.
Questionnaires will be dealt with according to question-
naire manuals. The prevalence of chronic local pain,
chronic widespread pain, fibromyalgia, and mental
comorbidities will be determined for the population-
based sample and tertiary care setting. Explorative clus-
ter analysis will be conducted to establish subgroups
based on the clinical manifestations observed. Therefore,
the dimensions of pain (see above) and mental comor-
bidity will be used as cluster variables. Then, we will
explore whether different neurobiological profiles (QST
profiles, CPM, NGF levels, EC profiles) correspond
with these subgroups. Pain drawings will be scanned,
superimposed, and transformed into two-dimensional
color-coded images. Body areas with high occurrence
of pain will be illustrated in dark red; body areas without
pain will appear in white. To classify patients who suffer
chronic local pain (CLP) or chronic widespread pain
(CWP), pain drawings will be analysed according to the
ACR criteria [62] and a more precise definition [6].
Quantitative sensory testing (QST) data pre-processing
and statistical analysis will be performed according to
the protocol established by Rolke et al. [76]. To quantify
conditioned pain modulation (CPM), the PPT before
PHP will be subtracted from the PPT after PHP. Nega-
tive values indicate an analgesic effect due to CPM. Dif-
ferences between patient groups will be analysed using
analyses of co-variance (ANCOVA), followed by Fisher’s
least significant difference test. Potential confounders
will be included as covariates, if indicated. QST modal-
ities or CPM will be entered as dependent variables, the
patient groups as an independent variable. For more
detailed information analysing QST data, we will refer tothe protocol proposed by Rolke et al. [76]. The same
procedure will be applied with regard to nerve growth
factor (NGF) and endocannabinoids (ECs).
Discussion
Establishment of a mechanism-based subgroup classifi-
cation of pain and the development of specific treat-
ments were suggested almost a decade ago [41]. Since
then, the topic has been discussed amid controversy
[19,22,87,88]. Small effect sizes of chronic pain treat-
ments were suspected to be due to unspecific treatment
approaches, but different pain generating and maintain-
ing mechanisms [19,20]. This possibly is also supported
by clinical experience, which shows that the subgroups
of chronic pain patients are heterogeneous, even if suf-
fering the same disease like non-specific chronic back
pain. However, only a few studies have aimed to identify
different pain mechanisms [20,21]. The identification of
patient subgroups is needed if we wish to establish dis-
tinct pathophysiological mechanisms and targets that are
necessary for the development of new analgesic drugs
and non-pharmacological mechanism-based treatment
options. There is a corresponding lack of evidence for
subgroup-specific treatments.
In addition to the identification of specific patho-
physiological mechanisms, we will implement a feasibil-
ity study that is designed as a randomised controlled
trial. We will adapt the proven Eye-Movement-
Desensitization-Reprocessing (EMDR) short-time ther-
apy to the subgroup of patients with chronic pain who
have experienced psychological trauma. This approach
might be promising because EMDR is an effective treat-
ment for patients with PTSD [89,90] or chronic pain
[91-94] but has not yet been adapted to patients with
chronic musculoskeletal pain who have experienced psy-
chological trauma. However, there are initial signs that
this might be a promising approach [95,96]. To identify
potential underlying mechanisms, we will use all mea-
surements of our study obtained before and after treat-
ment (plus functional magnetic resonance imaging).
Thus, our study will foster the development of new,
more specific interventions for chronic pain patients.
The remaining challenge is to match a sign or symp-
tom to a mechanism, but a sign or symptom could po-
tentially be produced by several distinct mechanisms
[19,20]. The novel aspect of our research is therefore its
comprehensive approach that uses reliable and valid
diagnostic tools. This approach comprises many vari-
ables that have been shown to be involved in alterations
in sensory processing (e.g., mental comorbidity, descend-
ing pain modulating systems, nerve growth factor, endo-
cannabinoids). A holistic approach is also needed
because research shows that these variables influence
each other [35]. The observed alterations might be
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The inclusion of a population-based sample is also rea-
sonable because prior research is usually based on highly
selective clinical samples of pain patients, and this might
bias research. Notably, the study is part of the LOGIN
consortium. LOGIN comprises seven subprojects and
includes basic and applied research in animals and
humans as well as preclinical and clinical projects. All
projects will use a core set of variables that investigates
similar pathogenetic mechanisms. This approach enables
LOGIN to study aspects in animals that cannot be inves-
tigated in humans (e.g., pathophysiological processes in
the spinal cord or brain) and to transfer results to the
human subprojects and vice versa. This approach will be
fostered by the translational aspects of LOGIN. Thus,
using the synergy of the different subprojects, the con-
temporary translation, implementation and dissemin-
ation of the results will be guaranteed.
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